BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cowper SE, Rabach M, Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol. 2008;66:191-199. [PMID: 18325705 DOI: 10.1016/j.ejrad.2008.01.016] [Cited by in Crossref: 89] [Cited by in F6Publishing: 70] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Leiner T, Michaely H. Advances in contrast-enhanced MR angiography of the renal arteries. Magn Reson Imaging Clin N Am 2008;16:561-72, vii. [PMID: 18926422 DOI: 10.1016/j.mric.2008.07.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
2 Bhargava V, Singh K, Meena P, Sanyal R. Nephrogenic systemic fibrosis: A frivolous entity. World J Nephrol 2021;10:29-36. [PMID: 34136369 DOI: 10.5527/wjn.v10.i3.29] [Reference Citation Analysis]
3 Ghio AJ, Soukup JM, Dailey LA, Richards J, Deng Z, Abraham JL. Gadolinium exposure disrupts iron homeostasis in cultured cells. J Biol Inorg Chem 2011;16:567-75. [PMID: 21267611 DOI: 10.1007/s00775-011-0757-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
4 Chiorean L, Tana C, Braden B, Caraiani C, Sparchez Z, Cui XW, Baum U, Dietrich CF. Advantages and Limitations of Focal Liver Lesion Assessment with Ultrasound Contrast Agents: Comments on the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) Guidelines. Med Princ Pract. 2016;25:399-407. [PMID: 27318740 DOI: 10.1159/000447670] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
5 Basak P, Jesmajian S. Nephrogenic systemic fibrosis: current concepts. Indian J Dermatol 2011;56:59-64. [PMID: 21572795 DOI: 10.4103/0019-5154.77555] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
6 Miyamoto J, Tanikawa A, Igarashi A, Hataya H, Kobayashi K, Ikegami M, Sotome A, Nagai Y, Kameyama K, Ishiko A. Detection of iron deposition in dermal fibrocytes is a useful tool for histologic diagnosis of nephrogenic systemic fibrosis. Am J Dermatopathol 2011;33:271-6. [PMID: 21389836 DOI: 10.1097/DAD.0b013e3181f63eb1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
7 Igreja ACDSM, Mesquita KDC, Cowper SE, Costa IMC. Nephrogenic systemic fibrosis: concepts and perspectives. An Bras Dermatol 2012;87:597-607. [DOI: 10.1590/s0365-05962012000400013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
8 Clément O, Faye N, Fournier L, Siauve N, Frija G. Rein et produits de contraste iodés et gadolinés. Journal de Radiologie 2011;92:291-8. [DOI: 10.1016/j.jradio.2011.02.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
9 Fretellier N, Idée J, Bruneval P, Guerret S, Daubiné F, Jestin G, Factor C, Poveda N, Dencausse A, Massicot F, Laprévote O, Mandet C, Bouzian N, Port M, Corot C. Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide. Br J Pharmacol 2012;165:1151-62. [PMID: 21740412 DOI: 10.1111/j.1476-5381.2011.01585.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
10 Pao VY, Chang S, Shoback DM, Bikle DD. Hypercalcemia and overexpression of CYP27B1 in a patient with nephrogenic systemic fibrosis: clinical vignette and literature review. J Bone Miner Res 2009;24:1135-9. [PMID: 19113910 DOI: 10.1359/jbmr.081261] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
11 Thomsen HS, Marckmann P, Logager VB. Update on nephrogenic systemic fibrosis. Magn Reson Imaging Clin N Am. 2008;16:551-560, vii. [PMID: 18926421 DOI: 10.1016/j.mric.2008.07.011] [Cited by in Crossref: 63] [Cited by in F6Publishing: 48] [Article Influence: 4.8] [Reference Citation Analysis]
12 Natalin RA, Prince MR, Grossman ME, Silvers D, Landman J. Contemporary applications and limitations of magnetic resonance imaging contrast materials. J Urol 2010;183:27-33. [PMID: 19913804 DOI: 10.1016/j.juro.2009.09.029] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
13 Boghosian M, Cassel K, Hammes M, Funaki B, Kim S, Qian X, Wang X, Dhar P, Hines J. Hemodynamics in the cephalic arch of a brachiocephalic fistula. Med Eng Phys 2014;36:822-30. [PMID: 24695337 DOI: 10.1016/j.medengphy.2014.03.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
14 Hao D, Ai T, Goerner F, Hu X, Runge VM, Tweedle M. MRI contrast agents: basic chemistry and safety. J Magn Reson Imaging 2012;36:1060-71. [PMID: 23090917 DOI: 10.1002/jmri.23725] [Cited by in Crossref: 188] [Cited by in F6Publishing: 146] [Article Influence: 23.5] [Reference Citation Analysis]
15 Kribben A, Witzke O, Hillen U, Barkhausen J, Daul AE, Erbel R. Nephrogenic Systemic Fibrosis. Journal of the American College of Cardiology 2009;53:1621-8. [DOI: 10.1016/j.jacc.2008.12.061] [Cited by in Crossref: 123] [Cited by in F6Publishing: 85] [Article Influence: 10.3] [Reference Citation Analysis]
16 Shellock FG, Spinazzi A. MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis. AJR Am J Roentgenol. 2008;191:1129-1139. [PMID: 18806155 DOI: 10.2214/ajr.08.1038.1] [Cited by in Crossref: 154] [Cited by in F6Publishing: 27] [Article Influence: 11.8] [Reference Citation Analysis]
17 Giorgi H, Ammerman J, Briffaux J, Fretellier N, Corot C, Bourrinet P. Non-clinical safety assessment of gadoterate meglumine (Dotarem®) in neonatal and juvenile rats. Regulatory Toxicology and Pharmacology 2015;73:960-70. [DOI: 10.1016/j.yrtph.2015.09.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
18 Edward M, Quinn JA, Burden AD, Newton BB, Jardine AG. Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation. Radiology 2010;256:735-43. [PMID: 20663970 DOI: 10.1148/radiol.10091131] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 4.1] [Reference Citation Analysis]
19 de Kerviler E, Maravilla K, Meder J, Naggara O, Dubourdieu C, Jullien V, Desché P. Adverse Reactions to Gadoterate Meglumine: Review of Over 25 Years of Clinical Use and More Than 50 Million Doses. Invest Radiol 2016;51:544-51. [DOI: 10.1097/rli.0000000000000276] [Cited by in Crossref: 24] [Cited by in F6Publishing: 6] [Article Influence: 4.8] [Reference Citation Analysis]
20 Bianchetti L, Barczyk M, Cardoso J, Schmidt M, Bellini A, Mattoli S. Extracellular matrix remodelling properties of human fibrocytes. J Cell Mol Med 2012;16:483-95. [PMID: 21595824 DOI: 10.1111/j.1582-4934.2011.01344.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 4.7] [Reference Citation Analysis]
21 Brücher E, Tircsó G, Baranyai Z, Kovács Z, Sherry AD. Stability and Toxicity of Contrast Agents. In: Merbach A, Helm L, Tóth É, editors. The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging. Chichester: John Wiley & Sons, Ltd; 2013. pp. 157-208. [DOI: 10.1002/9781118503652.ch4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
22 Zelasko S, Hollingshead M, Castillo M, Bouldin TW. CT and MR imaging of progressive dural involvement by nephrogenic systemic fibrosis. AJNR Am J Neuroradiol 2008;29:1880-2. [PMID: 18854445 DOI: 10.3174/ajnr.A1225] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Haneder S, Kucharczyk W, Schoenberg SO, Michaely HJ. Safety of Magnetic Resonance Contrast Media: A Review With Special Focus on Nephrogenic Systemic Fibrosis. Topics in Magnetic Resonance Imaging 2015;24:57-65. [DOI: 10.1097/rmr.0b013e3182a14e79] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
24 Wiedemeyer K, Kutzner H, Abraham JL, Thakral C, Carlson JA, Tran TA, Hausser I, Hartschuh W. The Evolution of Osseous Metaplasia in Localized Cutaneous Nephrogenic Systemic Fibrosis: A Case Report. The American Journal of Dermatopathology 2009;31:674-81. [DOI: 10.1097/dad.0b013e3181a1fb55] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
25 Fretellier N, Maazouz M, Luseau A, Baudimont F, Jestin-mayer G, Bourgery S, Rasschaert M, Bruneval P, Factor C, Mecieb F, Idée J, Corot C. Safety profiles of gadolinium chelates in juvenile rats differ according to the risk of dissociation. Reproductive Toxicology 2014;50:171-9. [DOI: 10.1016/j.reprotox.2014.10.024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
26 Morcos SK, Haylor J. Pathophysiology of nephrogenic systemic fibrosis: A review of experimental data. World J Radiol. 2010;2:427-433. [PMID: 21179310 DOI: 10.4329/wjr.v2.i11.427] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
27 Bryant B, Im K, Broome D. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI. Clinical Radiology 2009;64:706-13. [DOI: 10.1016/j.crad.2009.04.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
28 Marckmann P, Skov L. Nephrogenic Systemic Fibrosis: Clinical Picture and Treatment. Radiologic Clinics of North America 2009;47:833-40. [DOI: 10.1016/j.rcl.2009.05.004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
29 Thakral C, Abraham JL. Gadolinium-Induced Nephrogenic Systemic Fibrosis Is Associated with Insoluble Gd Deposits in Tissues: In Vivo Transmetallation Confirmed by Microanalysis. Journal of Cutaneous Pathology 2009;36:1244-54. [DOI: 10.1111/j.1600-0560.2009.01283.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 4.8] [Reference Citation Analysis]
30 Fu L, Li J, Yang X, Wang K. Gadolinium-promoted cell cycle progression with enhanced S-phase entry via activation of both ERK and PI3K signaling pathways in NIH 3T3 cells. J Biol Inorg Chem 2009;14:219-27. [DOI: 10.1007/s00775-008-0442-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
31 Fretellier N, Bouzian N, Parmentier N, Bruneval P, Jestin G, Factor C, Mandet C, Daubiné F, Massicot F, Laprévote O, Hollenbeck C, Port M, Idée J, Corot C. Nephrogenic Systemic Fibrosis-Like Effects of Magnetic Resonance Imaging Contrast Agents in Rats with Adenine-Induced Renal Failure. Toxicological Sciences 2013;131:259-70. [DOI: 10.1093/toxsci/kfs274] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
32 Hellman RN. Gadolinium-induced nephrogenic systemic fibrosis. Semin Nephrol 2011;31:310-6. [PMID: 21784280 DOI: 10.1016/j.semnephrol.2011.05.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
33 Collidge T, Thomson P, Mark P, Willinek W, Roditi G. Is this really a true case of NSF following Gadovist exposure alone? Nephrology Dialysis Transplantation 2010;25:1352-3. [DOI: 10.1093/ndt/gfq014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
34 Morris MF, Zhang Y, Zhang H, Prowda JC, Silvers DN, Fawwaz RA, Prince MR. Features of nephrogenic systemic fibrosis on radiology examinations. AJR Am J Roentgenol 2009;193:61-9. [PMID: 19542396 DOI: 10.2214/AJR.08.1352] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 DaSilva M, O'Brien Deming M, Fligiel SE, Dame MK, Johnson KJ, Swartz RD, Varani J. Responses of human skin in organ culture and human skin fibroblasts to a gadolinium-based MRI contrast agent: comparison of skin from patients with end-stage renal disease and skin from healthy subjects. Invest Radiol 2010;45:733-9. [PMID: 20661146 DOI: 10.1097/RLI.0b013e3181e9436b] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
36 Bardin T, Richette P. Rheumatic manifestations of renal disease. Current Opinion in Rheumatology 2009;21:55-61. [DOI: 10.1097/bor.0b013e32831ca5c5] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
37 Thomsen HS. Nephrogenic Systemic Fibrosis: History and Epidemiology. Radiologic Clinics of North America 2009;47:827-31. [DOI: 10.1016/j.rcl.2009.05.003] [Cited by in Crossref: 76] [Cited by in F6Publishing: 61] [Article Influence: 6.3] [Reference Citation Analysis]
38 Fraum TJ, Ludwig DR, Bashir MR, Fowler KJ. Gadolinium-based contrast agents: A comprehensive risk assessment. J Magn Reson Imaging 2017;46:338-53. [PMID: 28083913 DOI: 10.1002/jmri.25625] [Cited by in Crossref: 168] [Cited by in F6Publishing: 117] [Article Influence: 42.0] [Reference Citation Analysis]
39 Keeley EC, Mehrad B, Strieter RM. Fibrocytes: bringing new insights into mechanisms of inflammation and fibrosis. Int J Biochem Cell Biol. 2010;42:535-542. [PMID: 19850147 DOI: 10.1016/j.biocel.2009.10.014] [Cited by in Crossref: 69] [Cited by in F6Publishing: 59] [Article Influence: 5.8] [Reference Citation Analysis]
40 Hope TA, High WA, Leboit PE, Chaopathomkul B, Rogut VS, Herfkens RJ, Brasch RC. Nephrogenic Systemic Fibrosis in Rats Treated with Erythropoietin and Intravenous Iron. Radiology 2009;253:390-8. [DOI: 10.1148/radiol.2532090580] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
41 Orteu CH, Ong VH, Denton CP. Scleroderma mimics - Clinical features and management. Best Pract Res Clin Rheumatol 2020;34:101489. [PMID: 32147386 DOI: 10.1016/j.berh.2020.101489] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
42 Idée JM, Port M, Dencausse A, Lancelot E, Corot C. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. Radiol Clin North Am 2009;47:855-69, vii. [PMID: 19744600 DOI: 10.1016/j.rcl.2009.06.006] [Cited by in Crossref: 65] [Cited by in F6Publishing: 50] [Article Influence: 5.4] [Reference Citation Analysis]
43 Carr TF. Pathophysiology of Immediate Reactions to Injectable Gadolinium-based Contrast Agents. Topics in Magnetic Resonance Imaging 2016;25:265-8. [DOI: 10.1097/rmr.0000000000000108] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
44 Haneder S, Gutfleisch A, Meier C, Brade J, Hannak D, Schoenberg SO, Becker CR, Michaely HJ. Evaluation of a handheld creatinine measurement device for real-time determination of serum creatinine in radiology departments. World J Radiol 2012;4:328-34. [PMID: 22900135 DOI: 10.4329/wjr.v4.i7.328] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
45 Elmholdt TR, Olesen AB, Jørgensen B, Kvist S, Skov L, Thomsen HS, Marckmann P, Pedersen M. Nephrogenic systemic fibrosis in Denmark--a nationwide investigation. PLoS One 2013;8:e82037. [PMID: 24349178 DOI: 10.1371/journal.pone.0082037] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
46 Forghani R. Adverse Effects of Gadolinium-Based Contrast Agents: Changes in Practice Patterns. Top Magn Reson Imaging 2016;25:163-9. [PMID: 27367314 DOI: 10.1097/RMR.0000000000000095] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.8] [Reference Citation Analysis]
47 Idée J, Fretellier N, Robic C, Corot C. The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update. Critical Reviews in Toxicology 2014;44:895-913. [DOI: 10.3109/10408444.2014.955568] [Cited by in Crossref: 66] [Cited by in F6Publishing: 45] [Article Influence: 9.4] [Reference Citation Analysis]
48 Rahatli FK, Donmez FY, Kibaroglu S, Kesim C, Haberal KM, Turnaoglu H, Agildere AM. Does renal function affect gadolinium deposition in the brain? Eur J Radiol 2018;104:33-7. [PMID: 29857863 DOI: 10.1016/j.ejrad.2018.04.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
49 Bruce R, Wentland AL, Haemel AK, Garrett RW, Sadowski DR, Djamali A, Sadowski EA. Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide. Invest Radiol. 2016;51:701-705. [PMID: 26885631 DOI: 10.1097/rli.0000000000000259] [Cited by in Crossref: 34] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
50 Liu H, Zhang C, Tan Y, Wang J, Wang K, Zhao Y, Jia G, Hou Y, Wang S, Zhang J. Biodistribution and toxicity assessment of europium-doped Gd2O3 nanotubes in mice after intraperitoneal injection. J Nanopart Res 2014;16. [DOI: 10.1007/s11051-014-2303-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
51 Poff JA, Hecht EM, Ramchandani P. Renal Imaging in Patients with Renal Impairment. Curr Urol Rep 2011;12:24-33. [DOI: 10.1007/s11934-010-0158-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
52 Elmholdt TR, Jørgensen B, Ramsing M, Pedersen M, Olesen AB. Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol. NDT Plus 2010;3:285-7. [PMID: 28657062 DOI: 10.1093/ndtplus/sfq028] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
53 Perazella MA. Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: the perfect storm. Curr Opin Nephrol Hypertens 2009;18:519-25. [PMID: 19623065 DOI: 10.1097/MNH.0b013e3283309660] [Cited by in Crossref: 34] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
54 Fuah KW, Lim CTS. Erythema nodosum masking nephrogenic systemic fibrosis as initial skin manifestation. BMC Nephrol 2017;18:249. [PMID: 28738858 DOI: 10.1186/s12882-017-0666-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
55 Reiter T, Ritter O, Prince MR, Nordbeck P, Wanner C, Nagel E, Bauer WR. Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012;14:31. [PMID: 22607376 DOI: 10.1186/1532-429X-14-31] [Cited by in Crossref: 62] [Cited by in F6Publishing: 23] [Article Influence: 6.9] [Reference Citation Analysis]
56 Wagner B, Tan C, Barnes JL, Ahuja S, Davis TL, Gorin Y, Jimenez F. Nephrogenic systemic fibrosis: evidence for oxidative stress and bone marrow-derived fibrocytes in skin, liver, and heart lesions using a 5/6 nephrectomy rodent model. Am J Pathol 2012;181:1941-52. [PMID: 23041060 DOI: 10.1016/j.ajpath.2012.08.026] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
57 Maecker HT, Wang W, Rosenberg-Hasson Y, Semelka RC, Hickey J, Koran LM. An initial investigation of serum cytokine levels in patients with gadolinium retention. Radiol Bras 2020;53:306-13. [PMID: 33071374 DOI: 10.1590/0100-3984.2019.0075] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
58 Kelly BC, Markle LS, Vickers JL, Petitt MS, Raimer SS, McNeese C. The imbalanced expression of matrix metalloproteinases in nephrogenic systemic fibrosis. J Am Acad Dermatol 2010;63:483-9. [PMID: 20708474 DOI: 10.1016/j.jaad.2009.09.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
59 Radbruch A. The Gadolinium Deposition Debate and the Streetlight Effect: Should We Really Focus on the Brain? Radiology 2020;297:417-8. [PMID: 32813600 DOI: 10.1148/radiol.2020203143] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
60 Jenkins W, Perone P, Walker K, Bhagavathula N, Aslam MN, DaSilva M, Dame MK, Varani J. Fibroblast response to lanthanoid metal ion stimulation: potential contribution to fibrotic tissue injury. Biol Trace Elem Res 2011;144:621-35. [PMID: 21484406 DOI: 10.1007/s12011-011-9041-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
61 Elmholdt T, Pedersen M, Jørgensen B, Søndergaard K, Jensen J, Ramsing M, Olesen A. Nephrogenic systemic fibrosis is found only among gadolinium‐exposed patients with renal insufficiency: a case–control study from Denmark. British Journal of Dermatology 2011;165:828-36. [DOI: 10.1111/j.1365-2133.2011.10465.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
62 Thakral C, Abraham JL. Nephrogenic Systemic Fibrosis: Histology and Gadolinium Detection. Radiologic Clinics of North America 2009;47:841-53. [DOI: 10.1016/j.rcl.2009.06.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
63 Chopra T, Kandukurti K, Shah S, Ahmed R, Panesar M. Understanding nephrogenic systemic fibrosis. Int J Nephrol. 2012;2012:912189. [PMID: 23193473 DOI: 10.1155/2012/912189] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
64 Zou Z, Ma L, Li H. Incidence of nephrogenic systemic fibrosis at Chinese PLA General Hospital. J Magn Reson Imaging 2009;30:1309-12. [DOI: 10.1002/jmri.21769] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
65 Costelloe CM, Amini B, Madewell JE. Risks and Benefits of Gadolinium-Based Contrast-Enhanced MRI. Seminars in Ultrasound, CT and MRI 2020;41:170-82. [DOI: 10.1053/j.sult.2019.12.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
66 Thomsen HS. Nephrogenic systemic fibrosis: a serious adverse reaction to gadolinium – 1997–2006–2016. Part 1. Acta Radiol 2016;57:515-20. [DOI: 10.1177/0284185115626480] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
67 Wang W, Lazar A. Diseases of collagen and elastic tissue. McKee's Pathology of the Skin. Elsevier; 2012. pp. 935-66. [DOI: 10.1016/b978-1-4160-5649-2.00021-4] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
68 Weng Q, Hu X, Zheng J, Xia F, Wang N, Liao H, Liu Y, Kim D, Liu J, Li F, He Q, Yang B, Chen C, Hyeon T, Ling D. Toxicological Risk Assessments of Iron Oxide Nanocluster- and Gadolinium-Based T1MRI Contrast Agents in Renal Failure Rats. ACS Nano 2019;13:6801-12. [DOI: 10.1021/acsnano.9b01511] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
69 Bhagavathula N, Dame MK, DaSilva M, Jenkins W, Aslam MN, Perone P, Varani J. Fibroblast response to gadolinium: role for platelet-derived growth factor receptor. Invest Radiol 2010;45:769-77. [PMID: 20714270 DOI: 10.1097/RLI.0b013e3181e943d2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
70 Fowler KJ, Saad NE, Linehan D. Imaging Approach to Hepatocellular Carcinoma, Cholangiocarcinoma, and Metastatic Colorectal Cancer. Surgical Oncology Clinics of North America 2015;24:19-40. [DOI: 10.1016/j.soc.2014.09.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]